SCOR (SCR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
4 Mar, 2026Executive summary
Achieved full-year net income of EUR 846 million to EUR 851 million and Return on Equity of 19.1% to 19.2% for 2025, both exceeding targets.
All business segments—P&C, Life & Health, and Investments—contributed to strong results, supported by disciplined execution of the Forward 2026 plan.
EUR 170 million in cost savings realized after two years, one year ahead of target, keeping management expenses flat year-over-year.
Proposed dividend of EUR 1.9 per share for 2025, up 5.6% from the previous year, establishing a new floor under the dividend ratchet policy.
Solvency ratio at 215%, at the upper end of the target range.
Financial highlights
Q4 2025 net income reached EUR 208 million (EUR 214 million adjusted), with an annualized ROE of 20.4% to 21.1%.
Full-year insurance revenue was EUR 15,378 million to EUR 15.4 billion, with management expenses at EUR 1,225 million.
FY 2025 combined ratio improved to 82.3% (down 4.0 pts YoY); Q4 2025 combined ratio at 80.9% (down 2.2 pts YoY).
Investment income on invested assets was EUR 209 million in Q4 and EUR 835 million for the year, with a return of 3.5% to 3.6%.
Operating cash flow for FY 2025 was EUR 1,169 million, up 29.5% year-over-year.
Outlook and guidance
Positive outlook for all business segments, supported by satisfactory January renewals and a diversified model.
Confident in maintaining a P&C combined ratio below 87% for 2026.
Regular income yield expected between 3.4% and 3.8% in 2026.
Continued focus on capital generation and disciplined underwriting, with growth as an outcome rather than a target.
L&H insurance service result exceeded updated Forward 2026 guidance.
Latest events from SCOR
- H1 2026 net income EUR 409m, ROE 19%, solvency 220%, P&C combined ratio 79.5%.SCR
Q2 2026 - Q1 2026 net income was EUR 225m, ROE 21.1%–21.7%, and solvency ratio rose to 220%.SCR
Q1 2026 - January 2026 renewals drove 14.8% EGPI growth and improved underwriting in a competitive market.SCR
Investor update - 9.6% EGPI growth driven by Specialty and Alternative Solutions, with stable profitability.SCR
Investor Update - Q2 net income EUR 226m, H1 EUR 425m, ROE 22.6%, solvency 210%, strong P&C and L&H.SCR
Q2 2025 - Forward 2026 targets 9% value growth, >12% ROE, higher-margin L&H, and robust reserves.SCR
Investor Day 2024 - Strong P&C and investments offset by L&H review one-offs; solvency robust at 203%.SCR
Q3 2024 - Q2 2024 net loss driven by L&H review, but P&C and solvency remain strong.SCR
Q2 2024 - Q1 2025 net income was EUR 200m, with 18.3% ROE and strong P&C and investment results.SCR
Q1 2025